The partnership announced in March between Johnson & Johnson subsidiary LifeScan and diabetes management company WellDoc has entered a new stage with a commercial partnership agreement, the companies announced yesterday. 

"We’ve made considerable progress in our important relationship with LifeScan, Inc., which began earlier this year via a development agreement and a Johnson & Johnson Innovation – JJDC, Inc. investment in WellDoc," Kevin McRaith, CEO of WellDoc, said in a statement. “Together, WellDoc and LifeScan will provide those living with Type 2 diabetes a best-in-class diabetes management solution with robust data analytics powered by BlueStar’s patented clinical and behavioral engine. We will facilitate national adoption of this innovative first-in-class digital health solution. Our goal is to help make a difference in the lives of millions of Americans living with this chronic disease while bringing the U.S. healthcare system cost-savings opportunities.”

Per the new agreement, the companies will integrate WellDoc’s FDA-cleared BlueStar diabetes management platform and mobile application with LifeScan’s OneTouch Verio Flex smartphone-connected blood glucose monitoring system. The ultimate goal is to create a combined offering that is data-driven, comprehensive, and reimbursible by payers.

BlueStar analyzes patient data, compares the data to past trends, and sends analytics to the patient’s healthcare team. The program is supported by motivational messages, behavioral coaching, and educational content, delivered right to the patient's mobile device. BlueStar is known for being the first reimbursable digital therapeutic.

When the companies first announced their partnership in March, WellDoc also raised an additional $7.5 million from Johnson & Johnson Innovation and other investors.